TrialJournal of biomedical science2026

Safety and antiviral activity of inhaled siRNA SNS812 for treatment of mild-to-moderate COVID-19: a phase 2 randomized trial.

Shey-Ying Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.